ライフサイエンスコーパス: isotretinoin

1 nancy, and in patients taking amiodarone and isotretinoin.

2 feel protected from the teratogenic risks of isotretinoin.

3 6%) and 191 controls (0.44%) were exposed to isotretinoin.

4 fore myeloablative therapy, followed by oral isotretinoin.

5 dent cases of IBD associated with the use of isotretinoin.

6 isk for IBD, including UC or CD, with use of isotretinoin.

7 higher than that used in previous studies of isotretinoin.

8 olved in the durable therapeutic response to isotretinoin.

9 with class D or X prescriptions, except for isotretinoin.

10 ytes that were treated with PPAR ligands and isotretinoin.

11 Isotretinoin (13-cis retinoic acid (13-cis RA)) is the m

12 Isotretinoin (13-cis retinoic acid) is frequently prescr

13 performed using the following search terms: isotretinoin, 13-cis-retinoic acid, Accutane, retinoids,

14 r RPE-related eye diseases and the acne drug isotretinoin (a retinoid cycle inhibitor) are discussed.

15 Isotretinoin, a known teratogen, is strictly regulated t

16 hich when severe, may require treatment with isotretinoin, a known teratogen.

17 Isotretinoin (Accutane) has been shown to slow the synth

18 acne treatment, such as oral antibiotics and isotretinoin (Accutane), have limited use.

19 Isotretinoin also blocked the slower, age-dependent accu

20 y treating the abcr(-/-) mice with Accutane (isotretinoin), an inhibitor of rhodopsin regeneration.

21 Isotretinoin, an effective anti-acne therapy, is a known

22 HPLC analysis of ocular retinoids after isotretinoin and an intense bleach showed decreased leve

23 sotretinoin) or immunotherapy (six cycles of isotretinoin and five concomitant cycles of ch14.18 in c

24 Apart from isotretinoin and hormonal therapy, no agents are availab

25 published and unpublished studies assessing isotretinoin and IBD used a random-effects model to esti

26 conflicting regarding an association between isotretinoin and inflammatory bowel disease.

27 Terms related to acne treatment, isotretinoin, and diagnostic procedures were searched wi

28 sacea unresponsive to oral doxycycline, oral isotretinoin, and topical tacrolimus.

29 therapies, such as corticosteroids, dapsone, isotretinoin, and/or antibiotics.

30 eptives in acne, and the use and efficacy of isotretinoin are also addressed.

31 suggests that significantly higher doses of isotretinoin are effective for treating acne and decreas

32 ivermectin, as well as oral doxycycline and isotretinoin, are associated with improvements in rosace

33 opathic PPD, and it is important to consider isotretinoin as a potential inciting agent.

34 Perceptions of isotretinoin-associated risks and understanding of ways

35 f isotretinoin) or retrial (retreatment with isotretinoin) at 12-month follow-up and adverse effects

36 Isotretinoin blocked the formation of A2E biochemically

37 Isotretinoin does not impair PSA decline or add signific

38 This study demonstrates that isotretinoin exerts immunomodulatory effects in patients

39 wel disease developed less frequently in the isotretinoin-exposed group vs the nonexposed group (0.9%

40 tinoin, new strategies for reducing rates of isotretinoin-exposed pregnancies are needed.

41 However, isotretinoin-exposed pregnancies continue to occur.

42 Risk of IBD among isotretinoin-exposed vs non exposed patients.RESULTS Bot

43 p included the patients with confirmed prior isotretinoin exposure (n = 576), and the nonexposed grou

44 The negative association between isotretinoin exposure and IBD remained after adjusting f

45 ily seeking acne treatment were reviewed for isotretinoin exposure.

46 ainly in patients with acne with and without isotretinoin exposure.DESIGN, SETTING, AND PARTICIPANTS

47 ry testing for use of standard doses of oral isotretinoin for the standard patient with acne.

48 lower extremities 2 months after initiating isotretinoin for the treatment of refractory nodulocysti

49 ogen treatment to add (arm 1) or not (arm 2) isotretinoin from weeks 1 to 12.

50 1 discontinued while patients in arm 2 added isotretinoin from weeks 14 to 25.

51 sequent treatment with 13-cis-retinoic acid (isotretinoin) further improves event-free survival.

52 Oral isotretinoin has been associated with several adverse ef

53 tive trials include the possible activity of isotretinoin in never and former smokers and that of alp

54 both showed slow recovery from bleach after isotretinoin in rats and in mice.

55 nol, retinyl palmitate, N-acetylcysteine, or isotretinoin in smokers.

56 n MEK inhibitors (trametinib) and retinoids (isotretinoin) in primary nf1a-/- zebrafish neuroblastoma

57 y be a useful addition to efforts to prevent isotretinoin-induced birth defects.

58 to our knowledge the first reported case of isotretinoin-induced PPD.

59 We hypothesized that isotretinoin induces remission of acne by normalizing th

60 Isotretinoin is a pro-drug for all-trans retinoic acid,

61 Isotretinoin is a widely prescribed medication for nodul

62 This meta-analysis showed that (1) isotretinoin is associated with a statistically signific

63 Isotretinoin is frequently prescribed for the treatment

64 Participants clearly understood that isotretinoin is teratogenic but had less understanding o

65 Oral isotretinoin is the most effective therapy and is used e

66 Isotretinoin is the most effective treatment for acne.

67 IMPORTANCE Isotretinoin is the standard treatment for refractory se

68 13 cis Retinoic acid (isotretinoin) is a retinoid with preclinical evidence of

69 Finally, the results suggest that isotretinoin may be an effective treatment for other for

70 nflammatory and immune-modulating effects of isotretinoin may be worth exploring.

71 Further, they suggest that treatment with isotretinoin may inhibit lipofuscin accumulation and thu

72 the iPLEDGE program increases anxiety about isotretinoin more than it helps women feel protected fro

73 ntly reduced rates of pregnancies exposed to isotretinoin, new strategies for reducing rates of isotr

74 Accordingly, we tested the effects of isotretinoin on lipofuscin accumulation in abcr(-/-) kno

75 were defined as patients who never received isotretinoin or received it after the diagnosis of IBD (

76 , to receive standard therapy (six cycles of isotretinoin) or immunotherapy (six cycles of isotretino

77 al or oral acne medication after a course of isotretinoin) or retrial (retreatment with isotretinoin)

78 Exclusion criteria were use of modified isotretinoin products, isotretinoin therapy for conditio

79 Isotretinoin reduced Ca2+ entry in HaCaT cells and decre

80 ncluded 1078 patients from 1995 to 2011,with isotretinoin referenced in their medical records, and wh

81 Frequent isotretinoin-related toxicity included grade 1 cheilitis

82 Isotretinoin significantly decreased lipogenesis, while

83 Treatment of patients with isotretinoin significantly decreased monocyte TLR-2 expr

84 showed, however, that even a single dose of isotretinoin slowed the recovery of rod signaling after

85 The notion that systemic isotretinoin taken within 6 to 12 months of cutaneous su

86 14.18, GM-CSF, and interleukin-2 to standard isotretinoin therapy after intensive multimodal therapy

87 cuss the pathophysiologic characteristics of isotretinoin therapy and the likely causative role that

88 were use of modified isotretinoin products, isotretinoin therapy for conditions other than acne vulg

89 Systemic isotretinoin therapy has achieved nearly complete resolu

90 based estimates of laboratory changes during isotretinoin therapy in large patient samples are limite

91 Although rare, lip abscesses related to isotretinoin therapy present with substantial morbidity

92 ediately following the cessation of systemic isotretinoin therapy.

93 ently receiving or having recently completed isotretinoin therapy.

94 rgical procedures in the setting of systemic isotretinoin therapy.

95 antigen (PSA) decline and toxicity of adding isotretinoin to hormonal therapy and, secondarily, the p

96 esponsible for night vision, we administered isotretinoin to rats to learn whether night blindness re

97 tudy participants were 16 women who had used isotretinoin to treat severe skin disease and who were r

98 ecause the lesions began after initiation of isotretinoin treatment and resolved shortly after its te

99 for both the clinician and the patient when isotretinoin treatment is indicated.OBJECTIVE To assess

100 At 1 year after completion of isotretinoin treatment, we found that patients receiving

101 e not recommended in the setting of systemic isotretinoin treatment.

102 cystic acne.A true association between prior isotretinoin use and development of inflammatory bowel d

103 1, 2013) to identify all relevant studies of isotretinoin use in acne vulgaris.

104 not show an increased risk of IBD with prior isotretinoin use.

105 Isotretinoin was also found to protect rat photoreceptor

106 tic surgery, scars, wound healing, acne, and isotretinoin was convened.

107 High-dose isotretinoin was given daily for 2 months and produced s

108 We believe isotretinoin was the most likely causative agent in this

109 oncerns regarding the use of antibiotics and isotretinoin will be addressed.

110 Patients received isotretinoin, with dosing based on the providers' judgme